Hims & Hers Health, Inc.
HIMS Mid CapHealthcare · Drug Manufacturers - Specialty & Generic
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additional
Hims & Hers Health, Inc. Stock at a Glance
Hims & Hers Health, Inc. (HIMS) is currently trading at $26.82 with a market capitalization of $6.2B. The 52-week range spans from $13.74 to $70.43; the current price is 61.9% below the yearly high. Year-over-year revenue growth stands at +3.8%.
💰 Dividend
Hims & Hers Health, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
14 analysts rate Hims & Hers Health, Inc. (HIMS) on consensus: Hold. The average price target is $26.61, implying -0.79% from the current price. Analyst price targets range from $21.00 to $35.00.
Hims & Hers Health, Inc.: The Investment Case in Detail
Hims & Hers Health, Inc. (HIMS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 72.92%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
The Bear Case
Revenue growth has slowed to just 3.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 253.72% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.
Valuation in Context
The EV/EBITDA multiple of 78.99x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
What to Watch Next
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 72.92% — indicates pricing power
- Positive free cash flow
- –Currently unprofitable
- –High leverage (D/E 253.72)
- –High volatility (Beta 2.4)
- –High short interest (32.57%)
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to above-average price swings, elevated short interest (32.57%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Hims & Hers Health, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news